Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. 10 stocks we like ...

Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...

An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...